Savient elects two to board
This article was originally published in Scrip
Savient Pharmaceuticals has appointed Dr William Owen and David Norton to its board of directors. Dr Owen currently serves as president of the University of Medicine & Dentistry of New Jersey. Mr Norton recently retired as company group chairman of global pharmaceuticals for Johnson & Johnson.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.